A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
This Phase 2 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach["@novel2024"].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06079190 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | GlaxoSmithKline |
| Enrollment | 367 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2023-10-20 00:00:00 |
| Completion Date | 2026-11-23 00:00:00 |
| Last Updated | 2025-11-14 00:00:00 |
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].
The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[@mechanismdriven2024].
This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial. Phase 2 trials build upon Phase 1 safety data to evaluate efficacy and identify optimal dosing regimens[@clinical2023].
Phase 2 studies typically:
The trial is being conducted at multiple centers worldwide, including:
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
The rigorous design of this clinical trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].
GSK4527226, also known as AL101, is a novel therapeutic agent developed by GlaxoSmithKline (GSK) for the treatment of Alzheimer's disease. This compound represents GSK's entry into the Alzheimer's disease therapeutic pipeline, joining other pharmaceutical companies in the race to develop disease-modifying treatments for this devastating condition.
GSK's decision to develop AL101 reflects:
While the specific molecular target of GSK4527226 is proprietary, based on the trial design and GSK's pipeline, several possibilities are under investigation:
Amyloid-Targeting Mechanisms:
Non-Amyloid Mechanisms:
The Phase 2 trial design with 3 dose arms suggests:
This trial specifically targets early Alzheimer's disease, reflecting the field's shift toward earlier intervention:
Benefits of Early Treatment:
Early AD Definition:
The trial incorporates biomarker assessments to:
Key biomarkers being measured:
The amyloid-targeting monoclonal antibody field has produced the first disease-modifying AD drugs:
| Antibody | Company | Mechanism | Approval Status |
|----------|---------|-----------|-----------------|
| Lecanemab | Biogen/Eisai | Aβ protofibril binding | Approved (2023) |
| Donanemab | Eli Lilly | N-terminal Aβ plaque binding | Approved (2024) |
| Gantenerumab | Roche | Full-length Aβ plaques | Withdrawn |
| Crenezumab | Genentech | Aβ oligomers | Discontinued |
These antibodies all demonstrated:
Small molecule BACE inhibitors faced challenges:
| Drug | Company | Status | Issue |
|-----|---------|--------|-------|
| Verubecestat | Merck | Discontinued | Negative cognition, liver toxicity |
| Lanabecestat | AstraZeneca | Discontinued | Liver toxicity |
| Elenbecestat | Eisai | Discontinued | Liver enzyme elevation |
GSK4527226's advantages may include:
Other Phase 2 AD drugs in development:
| Drug | Company | Mechanism | Trial |
|------|---------|-----------|-------|
| GV-971 | Shanghai Green Valley | Oligosaccharide | Approved China |
| Blarcamesine | Anavex | Sigma-1 agonist | Phase 2/3 |
| AL101 | GSK | TBD | Phase 2 (this trial) |
The trial uses a 3-arm parallel group design:
Randomization (1:1:1)
|
+--------------------+--------------------+
| | |
Placebo (n~122) Low Dose (n~122) High Dose (n~122)
| | |
| | |
52 weeks 52 weeks 52 weeks
| | |
+--------------------+--------------------+
|
Assessment: CDR-SB at weeks 52, 64, 76
Design Rationale:
The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) is the primary endpoint:
CDR-SB Components:
Clinical Meaningfulness:
Comprehensive safety monitoring:
A successful Phase 2 trial would:
AD treatment has evolved significantly:
| Treatment | Type | Effect |
|-----------|------|--------|
| Cholinesterase inhibitors | Symptomatic | Moderate cognitive benefit |
| Memantine | Symptomatic | Modest benefit in moderate-severe AD |
| Lecanemab | Disease-modifying | 27% slowed decline |
| Donanemab | Disease-modifying | 35% slowed decline |
GSK4527226, if approved, would enter a market with:
GSK's entry into AD therapeutics reflects: